Skip to main content

Summary

for people ages 21 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to determine whether text messages/messaging (TM) or a mobile application (app), compared with an educational website-control provided to all Veterans, can improve adherence to antiplatelet therapy among patients following acute coronary syndrome or percutaneous coronary intervention (ACS/PCI).

Official Title

Mobile Health Strategies for Veterans With Coronary Heart Disease

Details

Adherence to antiplatelet medications is critical to prevent life threatening complications (i.e., stent thrombosis); yet rates of non-adherence range from 21-57% by 12 months. Mobile technology through TM or mobile apps is a practical and inexpensive strategy to promote behavior change and enhance medication adherence. The three specific aims of this proposal are to: 1) determine preferences for content and frequency of TM to promote medication adherence through focus groups; 2) determine the most patient-centered app to promote adherence through a content analysis of all commercially available apps for medication adherence and focus groups centered on usability; and 3) compare adherence to antiplatelet medications in 225 Veterans post ACS/PCI through a randomized controlled trial. Participants will be randomized to either TM, mobile app, or website-control group. The focus groups will be stratified by low/high mobile phone use and sex.

Keywords

Coronary Heart Disease mobile health veterans cardiovascular disease medication adherence

Eligibility

You can join if…

Open to people ages 21 years and up

  • ≥ 21 years of age,
  • recent ACS or PCI within 1 week
  • new antiplatelet (thienopyridine) prescription

You CAN'T join if...

  • cognitive impairment
  • lack of English proficiency/literacy

Locations

  • John Muir Medical Center not yet accepting patients
    Concord, California, 94520, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03022669
Phase
Phase 2
Lead Scientist
Linda Park
Study Type
Interventional
Last Updated
January 1, 2017
I’m interested in this study!